# A novel protective mechanism in hemorrhagic shock

> **NIH NIH R01** · RHODE ISLAND HOSPITAL · 2022 · $222,950

## Abstract

The assessment of myocardial function in vivo following trauma and hemorrhage is implicated as one of
the most critical approaches to deciphering physiological mechanism and designing a therapeutic strategy. The
precise and accurate determination of the physiological function in preclinical animal models will provide
important evidence for developing an effectively therapy and unravelling the deep mechanism(s) attributable for
pathological disorders and therapeutic intervention. In vivo non-invasive approaches have served as a powerful
technology to elucidate these physiological functions. We and others have extensively used in vitro and invasive
methods to determine cardiac functioning in small animal studies, providing crucial analysis of cardiac
performance in experimental design. However, those approaches and methodological tools with in vitro and
invasive techniques were designed to be performed at the end stage of the study and at the expense of
euthanizing animals in the studies, which limits obtaining the in vivo assessment of cardiac performance in a
serial manner to monitor the progress of experimental studies. The deficiencies include the limitation of
measurements and the lack of real time monitoring. In this parent R01 grant, we will determine cardiac function
of mice that are subjected to hemorrhage and resuscitation, in vivo measurement of cardiac function by
echocardiographic assessment will be conducted in real time and in a non-invasive manner. We have employed
echocardiographic analysis of myocardial performance in mouse using the conventional ultrasound for
acquisition of data, however, false negative and positive signals, high background noise of imaging measurement
frequently occur due to the limitation of the low frequency of transducer. In order to ensure the rigorousness and
solidity of our study, we will request to include the most advanced technology by implementing a high-
resolution micro-ultrasound the Vevo® 3100 LT imaging system that is specifically designed for small
animals to determine in vivo cardiac function. The advantages with employment of the high resolution ultrasound
technology the Vevo® 3100 LT imaging systemin our research not only provide a comprehensive array of
accurate and serial analyses of cardiovascular function for the proposed studies, but it will also impact our long-
standing focus on studying physiological function in small animals by strengthening our ongoing support,
improving the knowledge of trainees, and benefiting the greater research community and NIH-funded research.

## Key facts

- **NIH application ID:** 10593236
- **Project number:** 3R01GM141339-02S1
- **Recipient organization:** RHODE ISLAND HOSPITAL
- **Principal Investigator:** TING C ZHao
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $222,950
- **Award type:** 3
- **Project period:** 2021-07-01 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10593236

## Citation

> US National Institutes of Health, RePORTER application 10593236, A novel protective mechanism in hemorrhagic shock (3R01GM141339-02S1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10593236. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*